CorMedix (NASDAQ:CRMD) Earns “Buy” Rating from Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the stock. Other equities analysts also recently issued reports about the company. Leerink Partners initiated coverage on CorMedix […]
Needham & Company LLC reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. Needham & Company LLC currently has a $12.00 price objective on the stock. Other equities analysts also recently issued reports about the company. Leerink Partners initiated coverage on CorMedix […]